TAK 117

Drug Profile

TAK 117

Alternative Names: INK-1117; MLN-1117; TAK-117

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intellikine
  • Developer Baylor Research Institute; European Network for Translational Research in Ovarian Cancer (EUTROC); Takeda; Takeda Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Endometrial cancer; Renal cell carcinoma
  • Phase I/II Non-small cell lung cancer
  • Phase I Gastric cancer; Oesophageal cancer; Solid tumours

Most Recent Events

  • 19 Jun 2017 Phase-II clinical trials in Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03193853)
  • 18 May 2017 Avera McKennan Hospital & University Health Center plans a phase I trial for Solid tumours (Late-stage disease, Combination therapy) in USA (NCT03154294)
  • 01 Mar 2017 Millenium Pharmaceuticals terminates a phase I trial due to business decision and no safety or efficacy concerns in Solid tumours, gastric cancer and oesophageal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain, USA (PO) (NCT02551055)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top